Literature DB >> 23146489

Analytical validation of a homogeneous immunoassay for determination of mycophenolic acid in human plasma.

J M Vergara Chozas1, A Sáez-Benito Godino, N Zopeque García, S García Pinteño, I Joumady, C Carrasco García, F Vara Gil.   

Abstract

Mycophenolic acid (MPA) is an immunosuppression agent for the prophylaxis of organ rejection in patients receiving allogeneic transplants. The drug is administered based in 2 formulations, mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS). MPA acts by specific, reversible, uncompetitive inhibition of inosine monophosphate dehydrogenase (IMPDH) and thus blocks the proliferation of both T- and B-activated lymphocytes. Therapeutic drug monitoring (TDM) constitutes an important part of immunosuppressive treatment because of the demonstrated significant intraindividual and interindividual variability of its pharmacokinetic behavior. TDM is required to optimize immunosuppressive efficacy. We present the analytical validation of a homogeneous particle-enhanced turbidimetric inhibition immunoassay (PETINIA) technique for determination of MPA in human plasma, and compare with a homogeneous enzyme immunoassay technique (EMIT; reference method), both methods adapted on a Dimension analyzer (Siemens). We examined 50 human plasma samples from kidney transplant recipients treated with MMF or EC-MPA, which were analyzed simultaneously by both methods. The interassay precision was 5.95% at a concentration of 1.0 μg/mL, 3.47% at 7.5 μg/mL, and 3.75% at 12.0 μg/mL. The bias of PETINIA-MPA for each of the 3 quality control sample was <3.0%. Least squares linear regression yielded an r-value of 0.994 with the following linear regression equation: PETINIA = 0.939 * EMIT - 0.063. Bland-Altman comparison presented a mean negative difference of -0.312 μg/mL (standard deviation [SD], 0.441), namely, -7.6% for PETINIA-MPA. The PETINIA assay for monitoring MPA concentrations is an acceptable method for routine clinical use, with interassay imprecision (% coefficient of variation) ranging from 5.9% to 3.7% below and above the therapeutic concentration range, respectively. In conclusion, MPA-EMIT and PETINIA-MPA methods on Dimension analyzer have a good correlation (r = 0.994), but PETINIA-MPA method demonstrates a negative average difference of -7.6% in comparison with EMIT-MPA method.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23146489     DOI: 10.1016/j.transproceed.2012.09.063

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  4 in total

Review 1.  Clinical mycophenolic acid monitoring in liver transplant recipients.

Authors:  Hao Chen; Bing Chen
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine.

Authors:  Satoshi Hibino; Takuhito Nagai; Satoshi Yamakawa; Hidekazu Ito; Kazuki Tanaka; Osamu Uemura
Journal:  Clin Exp Nephrol       Date:  2016-04-22       Impact factor: 2.801

3.  When not to trust therapeutic drug monitoring.

Authors:  Mathew Westergreen-Thorne; Sook Yan Lee; Nilesh Shah; Alan Dodd
Journal:  Oxf Med Case Reports       Date:  2016-09-06

4.  Development of a Formula to Correct Particle-Enhanced Turbidimetric Inhibition Immunoassay Values so That it More Precisely Reflects High-Performance Liquid Chromatography Values for Mycophenolic Acid.

Authors:  Keiichi Nakano; Daiki Iwami; Takehiro Yamada; Ken Morita; Keiko Yasuda; Hitoshi Shibuya; Kaoru Kahata; Nobuo Shinohara; Chikara Shimizu
Journal:  Transplant Direct       Date:  2017-12-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.